San Diego is home to many amazing international companies in just about every sector. But true to the biotechnology sector in California, business is booming for several local online retailers of ELISA kits and other online reagent suppliers. In this case study, we are looking at how credit exchanged b2b is working to benefit startups in the technology world.
In the world of Biotech, there are many players. They are now attracting some of the world’s top talent to work here in the United States. The crucial difference that has transpired over the last decade is that many jobs that were previously outsourced overseas are now here in the US for good. With top talent int the biotech and biochemistry industry, and wages nearly double than the rest of the private sector, there are now more jobs and more companies than ever before. And California is not the only major player. Maryland and other states for example are home to some newer mega labs that do work requiring an in-depth knowledge of monoclonal and polyclonal antibodies, peptides, antigens and pathogen research. These companies are fueled by private investors many times but often they are supplied in advance by the manufacturers that supply reagents for testing in laboratories and medical facilities.
San Diego Biotechnology Loaners
In San Diego, there are many biotech companies that we have privy to who shall remain anonomyous but they are supplying such startup laboratories and research facilities and even some educational institutions with their first and second rounds of reagents supplies. The goal is not as philanthropic as it may sound, they are hoping for big returns on their investments. The labs who procure such loans have certain criteria that need to be followed in order to qualify for such programs, they include:
Unique abstracts around a long-studied pathogen
Top talent in the industry who are also working for less than they’re worth
Strong ties to either a medical or educational institution
Demonstrated vestment among several high-level employees
Business plan and go-to-market solutions for the outcome of their research
The ultimate goal is to gain equity in these smaller biotech startups. When the company becomes viable and makes an introduction into the pharmaceutical world, the original supplier of testing equipment is given a piece of the pie. This is risky for some companies but for others it is a write off. If the company has a large bumper crop of testing equipment which has a shelf life, then they are better off than discarding the supplies but “loaning” them or investing equity in a business.